Check out the ONYX website.
''Carfilzomib is a second-generation proteasome inhibitor that is being investigated as a potential treatment for patients with multiple myeloma and solid tumors. It is being studied in several clinical trials either as a single-agent or in combination with other therapies.''Are you trying to say that becuase ONYX hasnt come out and said one of their trials is with PAB'S PAT-SM6,that something is a miss,and our management are making things up?
Onyx Announcement???, page-28
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.229M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 38 | 43175478 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 10614841 | 12 |
View Market Depth
| Last trade - 16.12pm 01/11/2024 (20 minute delay) ? |
| PAB (ASX) Chart |
Day chart unavailable